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Abstract
Background: BMP-2 is known to accelerate fracture healing and might also enhance osseointegration and implant
fixation. Application of recombinant BMP-2 has a time-limited effect. Therefore, a gene transfer approach with a
steady production of BMP-2 appears to be attractive. The aim of this study was to examine the effect of locally
applied BMP-2 plasmids on the bone-implant integration in a non-weight bearing rabbit tibia model using a
comparatively new non-viral copolymer-protected gene vector (COPROG).
Methods: Sixty rabbits were divided into 4 groups. All of them received nailing of both tibiae. The verum group
had the nails inserted with the COPROG vector and BMP-2 plasmids using fibrin glue as a carrier. Controls were a
group with fibrin glue only and a blank group. After 28 and 56 days, these three groups were sacrificed and one
tibia was randomly chosen for biomechanical testing, while the other tibia underwent histomorphometrical
examination. In a fourth group, a reporter-gene was incorporated in the fibrin glue instead of the BMP-2 formula
to prove that transfection was successful.
Results: Implant fixation strength was significantly lower after 28 and 56 days in the verum group.
Histomorphometry supported the findings after 28 days, showing less bone-implant contact.
In the fourth group, successful transfection could be confirmed by detection of the reporter-gene in 20 of 22
tibiae. But, also systemic reporter-gene expression was found in heterotopic locations, showing an undesired
spreading of the locally applied gene formula.
Conclusion: Our results underline the transfecting capability of this vector and support the idea that BMP-2 might
diminish osseointegration. Further studies are necessary to specify the exact mechanisms and the systemic effects.
Keywords: BMP-2, gene transfer, non viral gene vector, COPROG, implant healing, fibrin glue
Background
Total hip and total knee arthroplasties (THA, TKA) in
the industrialized countries are increasing and demo-
graphic data suggest that this progress is going to con-
tinue [1-3]. According to the Swedish National Total Hip
Arthroplasty Register with more than 270,000 registered
THA from 1979-2006, the leading cause for component
failure in THA is aseptic implant loosening [4]. Besides
osteolysis due to wear debris (especially of polyethylene
components) it is assumed that a lack of initial bony
incorporation of the implant favors aseptic loosening.
Bone ingrowth does not occur properly if micromotion
exceeds 150 μm [5]. Therefore, many attempts have been
made to improve the incorporation of the implant. The
design of the prosthesis has a large impact on primary
stability. Modifications to the implant surface, such as
different micro- and macrostructures or osteoconductive
coatings (e.g. hydroxylapatite), have shown to play a deci-
sive role in improving primary as well as secondary stabi-
lity, due to bone ingrowth [6-8].
It is well accepted that certain growth factors (GF),
mostly members of the transforming growth-factor
superfamily, i.e. bone morphogenetic proteins (BMP) and
transforming growth factor b (TGF-b) promote bone for-
mation [9-11]. BMP-2 is well known to have high
osteoinductive potency and to improve bone healing. In
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common in the treatment of atrophic non-unions of
shaft-fractures, open tibial fractures and spine-fusions
[10]. In experimental studies also the improvement of
implant incorporation into bone has been shown under
the influence of BMP-2 [12,13] as well as of BMP-7
[14,15].
Regardless of the indication, providing a steady long-
term delivery of recombinant growth factors to the site
of action remains an unsolved problem. Therefore, the
i d e ao fag e n et r a n s f e rs y s t e mt oe s t a b l i s hac o n s t a n t
long-term but still temporally controlled local level of
GF at the wound site appears to be an attractive
method.
Gene therapy aims at the replacement of a defective or
missing gene or at the additional insertion of an existing
gene to start or stimulate the production of a certain
gene product, e.g. a growth factor.
A vector is needed to insert the gene into a target cell.
This vector is either of viral origin or it is a so called non-
viral vector. In the latter group, a variety of techniques are
used, including synthetic molecules or physical methods.
A vector should have properties which enable it to carry
the gene to the target cell and to invade the cell. Non-viral
vectors generally show a relatively poor potency in intro-
ducing nucleic acids into cells (transfection) compared to
viral vectors, where the introduction of nucleic acids into
cells (transduction) is part of the natural viral life cycle.
On the other hand, non-viral vectors are accepted to be
safer than their potentially mutagenic or immunogenic
viral counterparts [16,17].
The aim of this in vivo study was to investigate the
influence of a plasmid encoding BMP-2 on implant
incorporation in a non-weight bearing rabbit model. In
addition we studied the effectiveness of the promising,
comparatively new (non-viral) copolymer-protected gene
vector (COPROG) [18,19] as well as safety aspects.
Methods
All animal studies were approved by the proper authori-
ties (Landesamt für Arbeitsschutz, Gesundheitsschutz
und technische Sicherheit Berlin, Germany).
Sixty male New Zealand White rabbits (Harlaan-Winkel-
mann, Germany) with an average age of 8 months under-
went surgery.
As a carrier for the vector formula, we used commer-
cially available two component fibrin glue. Once
bonded, the glue would keep the drug formula at the
wound site. It has been proven that the incorporation of
t h ep l a s m i df o r m u l ad o e sn o tc h a n g et h ep r o p e r t i e so f
the glue, so that in can be applied as intended by the
manufacturer [20].
An established animal model was chosen for the in
vivo experiments. The rabbit tibia allows an easy
surgical approach and the possibility to transfect bone
tissue in New Zealand White Rabbits has already been
shown before [21].
Groups
The animals were divided in 4 groups. All animals
received anterograde intramedullary titanium nails (2.5
mm diameter) in both tibiae. A common two-component
fibrin sealant (Tissucol
®, Baxter, Germany) was used as
drug carrier, which was injected into the reamed tibia
(2.8 mm) before inserting the nail. The fibrinogen com-
ponent carried the gene vector.
There were three groups of 16 animals each and one
group of 12 animals: 1. a control group which received the
nail only, 2. a second control group (fibrin glue group)
which received the nail with fibrin glue but without plas-
mids, and the 3. the verum group, received the nail with
fibrin sealant and the plasmids. Half of the animals of each
group were sacrificed after 28 days and the other half after
56 days. The tibiae of each animal were randomly assigned
for either histomorphometry or biomechanics. In the
fourth group, 12 animals served as the reporter-gene con-
trol group and the animals were sacrificed at 4, 7 and 28
days. Luciferase, an enzyme normally only expressed by
the firefly, was used as the reporter-gene.
Non viral vector
The non viral vector used in this study is a Copolymer
Protected Gene Vector (COPROG). It consists of a posi-
tively charged polycation-Plasmid DNA polyplex coated
by a protective anionic peptide-PEG copolymer (PRO-
COP), which diminishes the susceptibility of the complex
to aggregation, to complement activation and interaction
with serum proteases [18]. The non viral vector, provided
in lyophilized form can easily be incorporated in the
fibrin-component of the fibrin glue. In the verum group, it
carried 84 micrograms of a plasmid encoding for human
BMP-2 (pB-BMP-2). In the Luciferase group, the glue was
carrying a plasmid encoding for the reporter-gene Lucifer-
a s e( p C M V - l u c ) .T h ep l a s m i d sw e r ea l s op r o v i d e db y
the Institute of Experimental Oncology, TU München,
G e r m a n y .T h ea m o u n to f8 4m i c r o g r a m so fp l a s m i d /
implant is based on the manufacturing procedure of the
plasmid/COPROG-mixture and represents the highest
possible “load” of COPROG to the fibrin component with-
out compromising the maximum clotting firmness (MCF)
of the fibrin glue.
Surgical procedure
After the animals were anaesthetized with Ketamine
(90 mg/kg body-weight) and Medetomidine (0.04 mg/
kg body-weight) both hind legs were shaved. Animals
were weighed, intubated and received analgesia with
Buprenorphine (0.3 ml i.m.). Perioperative antibiotic
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ately before the operation; inhalative narcosis was
maintained with isoflurane.
During the initiation of anaesthesia, the lyophilized
COPROG-formula was mixed with the thrombin compo-
nent of the fibrin glue. The operation was executed under
sterile conditions. After incision of the tibia, a hole of
3.2 mm diameter was drilled into the corticalis medial to
the tuberosity. Subsequently, the medullary cavity was
reamed first with a 2 mm hand brace, followed by 2.5 mm
and 2.8 mm. After measuring the length of the tunnel,
Titanium Elastic Nails (Synthes, Switzerland) of 2.5 mm
diameter were cut for later insertion. In all groups except
for the blank group, approximately 0.3 ml fibrin glue was
injected into the reamed marrow. The fibrinogen compo-
nent was injected first, followed by the thrombin part, car-
rying 200 μg of COPROG containing 84 μgo fB M P - 2
plasmid in the verum group or Luc-Plasmid in the Lucifer-
ase group. After that the implant was inserted in antero-
grade direction (Figure 1). In all animals, both tibiae were
operated the same way. After radiographic control of the
correct position of the nail, the wound was closed in
layers. Postoperative analgesia with Buprenorphine i.m.
was given for 2 days.
Radiographs
Radiographs were taken postoperatively and after the
animals were sacrificed, using standardized settings.
Biomechanical testing and histologic examination
Animals were sacrificed 28 days and 56 days after sur-
gery by intravenous injection of potassium chloride after
anaesthesia with Ketamine and Medetomidine. Both
tibiae were explanted and randomly assigned for the
biomechanical testing or prepared for histomorpho-
metric examination.
The biomechanical setup was designed to measure the
strength of the attachment of the implant-bone interface.
Therefore, we used a push-out device described by
Schmidmaier et al. 2002 [22], modified for the bigger rab-
bit tibia. After cutting off the distal and proximal epiphy-
sis, the bones were prepared carefully in order to reveal
about 4 mm of the nail at the distal and proximal end.
Subsequently, the tibia was inserted into the testing device
and the distal part of the diaphysis was embedded into
methyl-metacrylate (MMA). After the cement hardened,
the device was positioned into a material testing machine
(Zwick, Germany). The machine applied a constant linear
anterograde force at a rate of (2 mm/min.) onto the nail
and the force was measured and transferred to a compu-
ter. The maximum force at ultimate failure was used as
parameter for the bone-implant attachment strength. To
avoid impreciseness caused by different length of the
bones the peak force was set in ratio to the total bone area
surrounding the implant. The biomechanical testing
resulted in a typical curve with a sharp peak, expressing
the force needed to loosen the implant (Figure 2).
The contra-lateral tibiae were prepared for histomor-
phometrical examination:
After explantation, the proximal and the distal epiphy-
sis were removed to enable the fixation solution (10%
normal buffered formaldehyde) to infiltrate into the
whole specimen. Specimens were kept in the solution for
5 days followed by dehydration in ethanol of ascending
concentrations. Specimens were then embedded in
methyl- metacrylate (Technovit 7200, Heraeus-Kulzer,
Germany). After polymerization, the resulting blocks
including the specimens were cut in longitudinal direc-
tion using a cutting device (Exakt, Germany). They were
then ground using a grinding device (Exakt, Germany)
Figure 1 X-ray of the tibia postoperatively (a) a.p.-view (b)
lateral view.
Figure 2 A typical load-displacement curve with a peak at 72
N, describing the force needed to loosen the nail.
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face showing the maximum implant diameter of 2.5 mm.
The ground blocks showing the specimens were glued to
a microscope slide. The upper parts of the blocks were
removed using a diamond band saw (Exakt, Germany),
leaving slides of approximately 300 μm of MMA includ-
ing the specimens. These slides were ground down to
80 μm and staining was performed with Safranin-O and
van Kossa. For the histomorphometric analysis, the entire
specimen was scanned using a motorized stage with a
10 x objective and a digital camera attached to a micro-
s c o p e( L e i c aD M - R B ,L e i c a ,G e r m a n y ) .T h ed i g i t a l
pictures were combined with the use of a computer-
software (Mosaix, Zeiss, Germany).
To define the bone-implant contact as a sign of inte-
gration, the length of all sections where bone was tan-
gent to the implant was measured and set as a ratio to
the entire implant length, resulting in a percentage of
implant surface covered by bone. The analysis differen-
tiated between direct bone contact, where calcified tis-
sue was directly adjacent to the implant and indirect
contact, where bone had grown close to the implant,
but a gap was visible (see Figure 3).
Examination of the Luciferase group
I nt h eL u c i f e r a s eg r o u p ,w h e r eap l a s m i de n c o d i n gf o r
Luciferase replaced the BMP-2 encoding plasmid, ani-
mals were sacrificed at days 4, 7 and 28. Tissue from
the operated tibiae, brain, lungs, liver, spleen, testicles
and muscle was taken. Also bone samples from the not
operated forelegs were analyzed. The bone was grinded
with a cooled grinding device before processing. For
analysis, the tissue of the parenchymatous organs was
homogenized and lysed.
Total RNA was extracted using „RNeasy” Kit
® (Quia-
gen, Germany). Concentration and purity was deter-
mined photometrically at 260/280 nm. Approximately
80 ng of total RNA were used for Reverse Transcription
PCR. Thereby, single-stranded mRNA was transcribed
into complementary DNA (cDNA). In the following
non-quantitative PCR the luciferase transcripts were
amplified with specific luciferase primers (f 5’ ctg aat
aca aat cac aga atc gtc g 3’;r5 ’aaa tcc ctg gta atc cgt ttt
aga 3’). Additionally, the housekeeping gene GAPDH
(Glyceraldhyde-3-phosphate-Dehydrogenase) was ampli-
fied (f 5’gca tgt cag atc cac aac gga t 3’;r5 ’tgt cag caa
tgc atc ctg ca 3’). All PCR products were detected on
1.5% agarose gel (Serva) with Ethidiumbromide (Merck,
Germany).
Statistics
Animals were randomized in a blinded manner by draw-
ing lots before the operation. The tibiae (right or left)
were also randomized for histological and biomechanical
investigation.
To determine statistically significant differences in the
histomorphometrical and biomechanical results, a Krus-
kal Wallis followed by Mann-Whitney Test and Bonfer-
roni Holm correction was used (SPSS 14.0, SPSS Inc.,
Chicago, USA).
Results
One animal of the 28 days Luciferase group died during
anaesthesia and was excluded from the study. A connec-
tion to the vector administration could not be found. All
other animals tolerated the procedure well.
Neither the clinical appearance nor the blood speci-
mens suggested an infection at the wound site. In some
animals, a transient swelling at the nail insertion site
was observed.
Radiographic Examination
Radiographs showed that the implants were correctly
positioned and had a similar fitting in all animals. No
dislocations, fractures, or other abnormalities were
observed postoperatively or after scarifying. Radio-
graphic analysis did not reveal any difference between
the groups at any of the time points.
Biomechanical testing
Similar to the radiographic examination, gross observa-
tion revealed no fractures or abnormalities to any of the
bones. Throughout the groups, the recording of the test-
ing process showed a typical load-displacement curve
Figure 3 Histologic preparation stained with Safranin-O/van Kossa. Blue circles are marking a zone of direct bone contact, the yellow circle
marks a zone of indirect bone contact.
Faensen et al. BMC Musculoskeletal Disorders 2011, 12:163
http://www.biomedcentral.com/1471-2474/12/163
Page 4 of 9with a steep start and a peak, when the force needed to
loosen the implant had been reached (Figure 2). The
peak force was set in relation to the length of the tested
bone to compensate for differences in length between
the specimens. In the blank control group an increase in
the strength of fixation was detectable between day 28
and 56. This increase in implant fixation over time was
less pronounced in the two other groups. The strength
of fixation was significantly lower in the verum group at
both time points compared to the blank control group.
The difference between the blank control group with
no filling of the medullar cavity and the fibrin glue
group was not significant at either of the time points
(Figure 4).
Histomorphometric Analysis
At day 28 after operation, the measured direct and indirect
bone implant-contact was greatest in the blank control
group. The fibrin glue group showed almost the same
results for direct contact as for indirect contact. The
verum group showed significantly lower direct and indir-
ect contact compared to the other groups. These findings
support the biomechanical results after 28 days, where the
verum group showed significantly lower strength of fixa-
tion compared to the other groups.
After 56 days, the results of the verum group were
highest regarding the direct bone-implant contact, but
did not differ significantly from the blank control group.
Indirect contact was comparable in both groups. The
fibrin glue group showed the least amount of direct con-
tact after 56 days, while the indirect contact did not differ
significantly after 56 days (Figure 5).
Figure 4 Shear forces needed to loosen the implant.H i g h e s t
results were found in the control group after 56 days. *a p = 0.001
*b p = 0.005 *c p = 0.002. The boxes show the 25th and 75th
percentile and the band in the box is the 50th percentile (the
median). The whiskers represent the minimum and maximum of all
the data.
Figure 5 Direct and indirect bone-implant contact.a )D i r e c t
bone-implant contact: after 28 days significantly less direct contact
in the BMP-2 plasmid group. After 56 days the results were
comparable in all groups. b) Indirect bone-implant contact. Also,
significantly less in the BMP-2 plasmid group after 28 days. After 56
days, again comparable results of all groups. *a p = 0.02 *b p =
0.001. The boxes show the 25th and 75th percentile and the band
in the box is the 50th percentile (the median). The whiskers
represent the minimum and maximum of all the data.
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One animal of the Luciferase group died during
anaesthesia.
In 20 of the 22 explanted tibiae Luciferase was
detected. In two animals Luciferase could only be found
in one of the two tibiae (one of the 4 days group and
one of the 28 days group). This means that transfection
was successful in 90.9%.
Independent of the time point, luciferase-RNA could
be detected after 4, 7 and 28 days. Thus demonstrating
a successful transfection had been achieved.
However in the majority of animals, luciferase-RNA
was also found in other tissues besides the treated tibiae.
There was no obvious relationship between time points
and detection of luciferase-RNA, transfection of hetero-
topic organs took place without any pattern throughout
all groups (Table 1).
Discussion and Conclusion
Accelerated and improved implant integration could have
a significant impact on implant survival, reduction of
hospitalization and patient satisfaction. Several authors
have described improved bone-implant healing using
recombinant BMP-2 or other BMPs [23-25]. Gene ther-
apy offers a promising alternative to the direct applica-
tion of a recombinant protein by stimulating local target
cells to produce more of a desired product, e.g. a growth
factor for a period of time that lasts longer than a single
application of a recombinant protein. A vector is needed
to deliver the genetic information into the target cell.
Subsuming the differences between viral vectors and
non-viral methods, it is most important that non-viral
vectors are unable to match viral vectors concerning
their potency in transfecting the target cells. On the
other hand, viral vectors are believed to be not as secure,
i.e. being more at risk to cause problems due to immuno-
genicity or mutagenicity, whereas non-viral vectors are
believed to be safer. Unlike in systemic genetic disorders
where one might want to transfect a majority of target
cells of an individual by a systemic application of a gene
formula, in the case of tissue repair or regeneration only
a local effect is required and desired. A systemic transfec-
tion of cells would be an intolerable safety issue. In this
study it could be proven that a gene transfer using the
non-viral gene vector COPROG was achieved. Transfec-
tion could be confirmed by detecting the Luciferase
reporter-gene via rtPCR in the operated tibiae. Luciferase
RNA could be found in all of the 11 animals included in
the reporter-gene groups.
The biomechanical results did not meet the expectations
concerning the effect of BMP-2. A significantly weaker
i m p l a n ti n c o r p o r a t i o nw a sm e a s u r e da t2 8a n d5 6d a y s
after surgery when the BMP-2 plasmid was used. This
result corroborates the belief that BMP-2 under certain
conditions is also capable of impairing bone formation
rather than enhancing it. In recent years, many studies
have shown the potency of BMP-2 to promote bone heal-
ing. BMP-2 is commonly used clinically to accelerate bone
healing after fractures or in cases of non-union as well as
in spinal fusion. Some experimental studies showed an
improved bone-implant interface through the use of
recombinant BMP-2 protein [12,13]. However, there are
reports that the effect of BMP-2 can differ fundamentally
as the protein is not only capable of enhancing bone for-
mation but also of promoting its degradation by stimulat-
ing osteoclasts [26-28]. The circumstances under which
Table 1 Results of the Luciferase mRNA detection in bone and other organs
Specimen from operated tibia
animal brain lung liver spleen testicles muscle left/right
4d-1 neg. neg. neg. neg. neg. neg. pos./pos.
4d-2 (pos.) (pos.) neg. neg. (pos.) neg. pos./pos.
4d-3 neg. pos. neg. pos. (pos.) neg. neg./pos.
4d-4 pos. pos. pos. (pos.) pos. pos. pos./pos.
7d-1 neg. neg. neg. neg. (pos.) neg. pos./pos.
7d-2 neg. pos. neg. neg. neg. neg. pos./pos.
7d-3 neg. pos. (pos.) (pos.) (pos.) neg. pos./pos.
7d-4 (pos.) pos. neg. pos. pos. neg. pos./pos.
28d-2 neg. (pos.) (pos.) pos. pos. neg. neg./pos.
28d-3 neg. neg. (pos.) neg. (pos.) neg. pos./pos.
28d-4 neg. neg. (pos.) (pos.) pos. neg. pos./pos.
total: neg. 8 4 6 5 2 10 2
total: pos. 1 5 1 3 4 1 20
total: (pos.) 2 2 4 3 5 0 0
Detection of Luciferase mRNA in bone and other organs Number and kind of tissue in animals being positive for Luciferase RNA in heterotopic organs. pos.=
positive signal, (pos) = weak signal, neg. = no signal.
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tion in vivo is not yet clear. In 1996 Jepsson et al. found
unexpected inhibitory effects of BMP-2 on bone formation
in an established rabbit model. The experiment was
repeated in 1999 with variations in dosage, type of BMP
and other experimental design modifications. The inhibi-
tory effect was a consistent finding but a mechanism
responsible for it could not be determined [29]. Sena et al.
found a dosage dependent negative effect of TGF-ß2 on
strength of fixation and bone/implant contact in a well
established rat model. Interestingly, the bone volume was
increased in the TGF-ß2 treated animals [30]. Stadlinger
et al. ruled out a detrimental effect of BMP-4 on implant
integration in a miniature-pig model when different sur-
face modifications of collagen, collagen and chondroitin
sulfate and collagen, chondroitin sulfate and BMP-4 were
compared [31]. Liu et al showed in a pig model that differ-
ent modes of delivery for BMP-2 change the osteoconduc-
tivity of surfaces. Different surfaces (metal with/without
CaP coating) with or without incorporated or absorbed
BMP-2 were investigated. New bone formation was high-
est in the coated and uncoated groups bearing no BMP-2
followed by the groups where BMP-2 was incorporated in
a coated surface. The lowest results concerning deposited
bone were found in the coated implants bearing only
adsorbed BMP-2. As a second parameter in the study of
Liu et al. the interface coverage with bone was examined.
This was found highest for blank coated implants, fol-
lowed by coated implants bearing incorporated or incor-
porated and adsorbed BMP-2. The lowest results were
found in the uncoated implants bearing adsorbed BMP-2.
The authors conclude, that osteoconductivity of an
implant surface can be significantly influenced not only by
BMP-2 but also by the mode of delivery [32]. Egermann et
al. found a systemic inhibition of bone formation in a
sheep model after local application of adenoviral vectors
encoding BMP-2. The effect could be detected by a micro-
CT scan 8 weeks after creating standardized defects of the
iliac crests on both sides and unilateral local application of
Ad.BMP-2. The effect might have been connected to an
increased inflammatory response since the histological
analysis showed an elevated level of inflammatory cells at
the treated bone defects [33]. All these findings and the
results of our study are in contrast to the generally
accepted positive impact of BMP-2 in fracture healing.
Possibly the unexpected effects seen in our present study
also can be explained by the different ways new bone is
formed during secondary fracture healing and implant
integration. While in fracture healing bone formation
usually happens via a chondrogenesis and endochondral
ossification, unless anatomical repositioning is achieved,
implant integration occurs via [34]. BMP-2 is known to
promote an endochondral ossification pattern [35], which
could interfere with the primary bone-implant healing
process and by this account for the poor results of the
groups treated with BMP-2 plasmids compared to the
other groups.
The histological findings at day 28 supported the bio-
mechanical results. The BMP-2 plasmid group showed
the least direct and indirect bone contact. At day 56 the
biomechanical results were lowest for the BMP-2 plas-
mid group while the histomorphometry showed com-
parable direct bone-implant contact and indirect bone-
implant contact in all three groups, not elucidating the
biomechanical findings. Further conclusions how the
weak implant healing connects to the comparatively
large bone-implant contact zone could not be drawn
from this experimental design.
In a recent study Sena et al. saw a dose dependent low-
ering of bone implant contact and fixation strength in a
similar model, using a rat femur and different dosages of
r h T G F ß[ 3 0 ] .I nt h i ss t u d y ,r h T G F be n h a n c e db o n ef o r -
mation at dosages of 5, 10 and 20 micrograms/implant,
while at the same time all concentrations of rhTGFß low-
ered the bone-implant contact and fixation strength. The
authors concluded that for fixation strength the location
of bone formation is also important, in addition to the
amount of bone formation. These findings correlate with
our results. Despite a comparable bone-implant contact at
day 56, we did not see an improvement in fixation
strength.
I nt h eL u c i f e r a s eg r o u pt h er e p o r t e rg e n eL u c i f e r a s e
could also be found irregularly distributed in heterotopic
organs in 10 out of 11 animals. The application of the
COPROG/fibrin mixture had been performed with a great
deal of caution in order not to spread the formula else-
where than the wound site. Therefore, the most reasonable
explanation for the contamination might be the systemic
spread of the locally applied COPROGs due to the rising
of the intramedullary pressure during the insertion of the
implant. By this, vector loaded fibrin particles might have
been pushed into the venous vessels of the tibial bone
leading to a systemic distribution of the COPROGS - com-
parable to the pathogenesis of fat embolism during intra-
medullary nailing or total joint arthroplasties. Of the
systemically transfected organs, muscle tissue showed by
far the lowest transfection rate. It could only be found in 1
animal of the 4-day group.
In summary, it could be proven that transfection using
the copolymer protected gene vector was achieved, how-
ever without a stimulation of implant integration due to
the BMP-2 plasmid application. The systemic distribu-
tion of the vector, as we found in our reporter gene
groups, is not desired and demands further improve-
ment. Fibrin glue as a drug carrier was chosen to release
the plasmid formulation due to degradation of the fibrin
matrix. This mechanism had been described earlier[20].
The gene-therapeutic approach was used to provide a
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study supports findings that under certain circumstances
BMP-2 might impair implant integration. This work was
targeted as a proof of concept study and therefore has
limitations in providing information about the exact
mechanisms which led to the observed results, e.g. a
possible dose-dependent effect of BMP-2. But in this
study the proof of transfection in a large animal model
using the non-viral vector COPROG could be demon-
strated for the first time. The systemic effect means a
security risk on the one hand, but shows the capacity of
the formula to not only act locally.
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